EMED Technologies has appointed the first members to its newly-established Scientific Advisory Board (SAB).
The first trio of board members includes Jeffrey Allen, M.D., a renowned neurologist and expert in inflammatory neuropathies; Richard L. Wasserman, M.D., Ph.D., who specializes in immunodeficiencies, asthma, and food allergy; and John C. (Jack) Lewin, M.D., an expert in healthcare innovation and health policy.
“We are honored to collaborate with this distinguished group of internationally renowned physicians and scientists,” EMED Technologies CEO Paul Lambert stated. “Their deep expertise and insight will be invaluable as we advance our mission to improve drug delivery, and we look forward to the meaningful contributions they will bring.”
Dr. Allen, a professor of Neurology at the University of Minnesota, is a global expert in chronic inflammatory neuropathies, Guilian-Barre syndrome, generalized myasthenia gravis, and other neurological diseases. He is published widely on diagnosing and treating immune mediated neuropathies and has contributed to global clinical research and development of international guidelines for treating patients with CIDP, including immunoglobulin replacement therapy. Dr. Allen completed his residency at Tufts University School of Medicine, and fellowship at Harvard Medical Centers.
Dr. Wasserman is a highly skilled, civic-minded immunologist with a specialized focus on primary immunodeficiency and allergy treatments. He has extensive experience in clinical research as a principal investigator in national and international clinical trials of immunodeficiency treatments and has been an advisor and consultant to pharmaceutical and healthcare organizations. Dr. Wasserman received his medical degree from the University of Texas Southwestern Medical School, completed his pediatrics residency and a fellowship in bone marrow transplantation/immunology at the Children’s Hospital of Philadelphia, and postdoctoral fellowships in cancer/immunology at the University of Texas Southwestern Medical School and immunology/rheumatology at The Rockefeller University. Additionally, he received his Ph.D. in biomedical sciences from the University of New York, Mt. Sinai School of Medicine.
Dr. Lewin is an internationally recognized expert in health policy promoting healthy populations and a strong proponent of a more efficient, effective, and sustainable healthcare system. Dr. Lewin’s professional roles include chairman of the National Coalition on Health Care in Washington D.C.; CEO of the California Medical Association; president/CEO of the NYC-based Cardiovascular Research Foundation; CEO of the D.C.-based American College of Cardiology; and Hawaii Director of Health. He is founder/CEO of Lewin and Associates LLC in New York, N.Y., a health policy and healthcare innovation consulting firm focused on advising U.S. Congress, federal agencies, and the health sector. He has served as a top advisor for two former U.S. presidents as part of a career in healthcare, public health, and public policy.
The advisors will draw on their considerable expertise and depth of experience to advise the company and its leadership team on scientific and strategic matters at the intersection of technology, usability, and clinical outcomes. Their insights will help shape patient-centric solutions that raise the standard for health and drug delivery, supporting the development of next-generation systems that meet the needs of patients, healthcare providers, and pharmaceutical partners.
“We have established a scientific partnership with these incredible doctors who embody what EMED is about. I am honored to work with the Scientific Advisory Board on medical innovations, patient-centric technology, and clinical outcomes,” EMED Technologies Clinical Affairs Director Alex Nikanorov, M.D., Ph.D., said.
Established in 1991, EMED Technologies is a medical device company developing devices for subcutaneous infusion, supporting biologics, specialty drugs, and at-home treatments. The company has worked with patients, clinicians, and pharmaceutical companies to design, manufacture, distribute, and commercialize innovative drug delivery systems. EMED Technologies focuses on medical devices for subcutaneous infusion systems. Its devices deliver medications and fluids efficiently and safely to patients, particularly those requiring home care or chronic disease management. The firm’s devices include SCIg60, Infuset, VersaRate, VersaPump, and others for delivering treatments like immunoglobulin therapy and other injectable treatments.
link